The Fiscal Year 2005 (FY05) Appropriation Bill was signed by President Bush on August 5, 2004. This program announcement is being released prior to the receipt of funds appropriated in the bill for this research program; funding of proposals received in response to this program announcement is contingent on the receipt of funds at the United States Army Medical Research and Materiel Command (USAMRMC).
The United States Army Medical Research and Materiel Command (USAMRMC), Office of the Congressionally Directed Medical Research Programs (CDMRP) invites applications for funding for the FY05 Neurofibromatosis Research Program (NFRP) Clinical Trial Awards.
The goal of the Clinical Trial Award mechanism is to sponsor novel clinical research, specifically a Phase I or Phase II clinical trial that has the potential to substantially improve todays approach to the treatment and/or management of neurofibromatosis 1 (NF1), NF2, and/or Schwannomatosis. Please see announcement for complete details of this award mechanism.
Although there are no total dollar amount restrictions to these awards, programmatic priority will be given to smaller-scale, cost-efficient clinical trials. Approximately $2.8M is available for this award mechanism. Depending on the number and quality of the applications, it is anticipated that approximately one to two proposals will be funded.
Funding for Phase I clinical trials can be requested for up to 3 years, whereas funding for Phase II clinical trials can be requested for up to 4 years. Direct costs can cover salary, expenses including research supplies, and travel to scientific meetings. The amount for this travel may not exceed $1,800 per year per investigator. Applicants also should budget for travel to a pre-award meeting and protocol workshop at Fort Detrick, Maryland, and a reverse site visit in the Baltimore-Washington, DC area during the period of performance.
Applicants must provide evidence of sufficient institutional support and commitment for the proposed studies, such as the provision of access to adequate laboratory facilities and equipment. Consideration of cost sharing with other funding sources and multi-institutional/multidisciplinary research collaborations are encouraged. Applicants are encouraged to use the existing infrastructures of the NFRP-funded NF1 and NF2 natural history studies as infrastructures for their proposed clinical trials. The nature of this Program does not allow for renewal of grants or supplementation of existing grants with DOD funds.
Submission of the same research project to the FY05 NFRP under different award mechanisms or to other CDMRP programs is discouraged. The Government reserves the right to reject duplicative proposals.
Electronic submission is required. Proposals will be accepted only as PDF files submitted through the CDMRP eReceipt system. No paper copy submissions will be accepted. The CDMRP uses a two-tier review process for proposals: scientific peer review, followed by programmatic review. Details of both tiers of review can be found in the Full Text of Program Announcement.
Estimated timelines for the FY05 Clinical Trial Award proposals are as follows: Full Proposal Submission Deadline: February 22, 2005, 5:00 p.m. Eastern Time; Peer Review: April, 2005; Programmatic Review: July, 2005; Award Start Date: Between September, 2005 and January, 2006.
For additional information or questions, please contact: Patricia A. Evans, Contracting/Grants Office, U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Fort Detrick, MD 21702-5014, phone: (301) 619-7354, Fax: (301) 619-6662, email: email@example.com
Who can apply:
Eligible functional categories:
Military Medical Research and Development
FY05 Neurofibromatosis Research Program (NFRP) Clinical Trial Award (CTA Announcement
If you have problems accessing the full announcement, please contact:
US Army Medical Research Acquisition Activity, ATTN: MCMR-AAA, 820 Chandler Street, Frederick, MD 21702-5014